drugset / Trial / NCT00443209

Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)

NCT00443209

Phase 3 Completed 1068 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of telcagepant (MK-0974) in the long-term treatment of acute migraine in adult participants. The primary hypothesis of this study is that telcagepant is well tolerated in the long-term treatment of acute migraine in adult participants.

Timeline

Start
2007-02-21
Primary completion
2009-01-22
Completion
2009-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Telcagepant Small molecule 280 mg Oral
Subject Telcagepant Small molecule 300 mg Oral
Comparator rizatriptan Unknown 10 mg Oral

Indications